The largest study to date testing the ability of the psychedelic compound psilocybin to treat a psychiatric disorder has shown that the mushroom-derived drug, delivered in combination with integrative psychotherapy sessions, significantly reduced participants’ depression as compared to a placebo after three weeks.
If you need to quickly assess whether a patient might have cannabis use disorder, ask them how often they’ve used cannabis in the past year. At least, that is the suggestion put forward in new research published this week.
Writing in the Conversation, Benjamin Land, a research associate professor of pharmacology at the University of Washington, explains how cannabis could be used as an opioid substitute.
The certificate was awarded on October 20 to Viridis Laboratories, a cannabis lab in Michigan.
The state’s Office of Cannabis Management has removed the pass/fail limits associated with the total yeast and mold counts for cannabis flower and pre-rolls.
Chris Hudalla, president and chief scientific officer at ProVerde Laboratories, explores the legality and implications of novel synthetic cannabinoids.
Regulators in Colorado have found “potentially unsafe” levels of Aspergillus mold on batches of medical cannabis flower.
Joe Humphreys, business development manager at Eurofins Food & Water Testing, discusses the journey of CBD testing.
Genetec's Scott Thomas outlines the three security factors every entrepreneur should consider before opening their cannabis production facility.